Research Article| Volume 32, ISSUE 4, P744-757, April 2010

Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: A phase III, open-label, international multicenter study

      This paper is only available as a PDF. To read, Please Download here.


      Background: A microencapsulated, sustained-release formulation of leuprolide acetate 3.75 mg has been developed.
      Objective: This study investigated the effectiveness, pharmacokinetics, and safety profile of a 1-month leuprolide acetate 3.75-mg depot formulation for suppressing testosterone concentrations in patients with prostate cancer.
      Methods: This was a Phase III, open-label, international multicenter clinical trial. Patients with prostate cancer who, in the judgment of the investigators, could benefit from androgen deprivation therapy received 6 monthly intramuscular injections of leuprolide acetate 3.75-mg depot. Plasma testosterone concentrations were determined at specific times throughout the study. The primary end point was the proportion of successful patients over the total number of evaluable patients (ie, patients with evaluable testosterone concentrations at all monthly assessments and no missing values due to treatment-related adverse events). Treatment success was defined as testosterone suppression below the clinical castration level (ie, ≤0.5 ng/mL) at day 28 and maintenance of clinical castration until study completion (day 168). The frequency of patients with testosterone concentrations ≤0.2 ng/mL was also studied.
      Results: The study included 160 patients with a mean (SD) age of 71.6 (9.2) years, weight of 83.7 (15.5) kg, and predominantly white race (87.5% [140/160]). All 160 patients received at least one dose of study drug; 157 of them were fully evaluable, and 152 completed the study. The proportion of successful patients over the total number of evaluable patients was 96.8% (152/157; 95% CI,92.7%–99.0%). Five of the 157 evaluable patients (3.2%) did not achieve the primary end point of testosterone concentration ≤0.5 ng/mL by day 28. Of the evaluable patients, 78.7% (122/155) achieved testosterone suppression by day 21. By day 28, 96.8% (151/156) of the evaluable patients had achieved castrate levels, and 73.1% (114/156) achieved testosterone concentrations <0.2 ng/mL. At study end, 100% (152/152) of the patients completing the study maintained castrate levels, and 92.8% (141/152) had testosterone concentrations ≤0.2 ng/mL. The pharmacokinetic profile of leuprolide during the first 3 months of treatment, evaluated in a subset of the study population (n = 12), showed sustained release of leuprolide from the formulation. Values for AUC0−t calculated from day 0 to day 28, days 28 to 56, and days 56 to 84 were 25,976.5 (7892.0), 30,685.5 (9348.4), and 31,030.9 (10,745.0) pg/mL per day, respectively. The most common treatment-related adverse event was hot flashes (45.0% [72/160]). Fatigue, hyperhidrosis, night sweats, and headache each occurred in ≤6.3% (10/160) of the patients. The most frequently reported local adverse reaction was pain at the injection site, experienced by 8.1% (13/160) of the patients.
      Conclusions: Leuprolide acetate 3.75-mg depot was effective in achieving and maintaining testosterone suppression and was well tolerated throughout the study in this cohort of patients with prostate cancer. identifier: NCT00128531.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Prostate Cancer Foundation: Report to the Nation on Prostate Cancer 2004. 8BB6B1%7D/PCF%20Monograph-finall.pdf. Accessed. September 23, 2009
        • Huggins C
        Studies onprostaticcancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.
        J Urol. 2002; 168: 9-12
        • Perlmutter MA
        • Lepor H
        Androgen deprivation therapy in the treatment of advanced prostate cancer.
        Rev Urol. 2007; 9: S3-S8
        • McLeod D
        • Zinner N
        • Tomera K
        • et al.
        • Abarelix Study Group
        A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer.
        Urology. 2001; 58: 756-761
        • Persad R
        Leuprorelin acetate in prostate cancer: A European update.
        IntJ Clin Pract. 2002; 56: 389-396
        • Doehn C
        • Sommerauer M
        • Jocham D
        Degarelix for prostate cancer.
        Expert Opin Investig Drugs. 2009; 18: 851-860
        • Bergquist C
        • Nillius SJ
        • Bergh T
        • et al.
        Inhibitory effects on gonadotrophin secretion and gonadal function in men during chronic treatment with a potent stimulatory luteinizing hormone-releasing hormone analogue.
        Acta Endocrinol (Copenh). 1979; 91: 601-608
        • Moretti RM
        • Monagnani Marelli M
        • van Groeninghen JC
        • et al.
        Inhibitory activity of luteinizing hormone-releasing hormone on tumor growth and progression.
        Endocr Relat Cancer. 2003; 10: 161-167
        • D'Amico AV
        • Manola J
        • Loffiedo M
        • et al.
        6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial.
        JAMA. 2004; 292: 821-827
        • Gleave ME
        • Goldenberg SL
        • Chin JL
        • et al.
        • Canadian Uro-Oncology Group
        Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: Biochemical and pathological effects.
        J Urol. 2001; 166: 500-506
        • Smith MR
        Androgen deprivation therapy for prostate cancer: New concepts and concerns.
        Carr Opin Endocrinol Diabetes Obes. 2007; 14: 247-254
        • dejong IJ
        • Eaton A
        • Bladou F
        LHRH agonists in prostate cancer: Frequency of treatment, serum testosterone measurement and castrate level: Consensus opinion from a roundtable discussion.
        Curr Med Res Opin. 2007; 23: 1077-1080
        • Waxman JH
        • Wass JA
        • Hendry WE
        • et al.
        Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.
        Br Med J (Clin Res Ed). 1983; 286: 1309-1312
        • Mcleod DG
        Hormonal therapy: Historical perspective to future directions.
        Urology. 2003; 61: 3-7
        • Hellerstedt BA
        • Pienta KJ
        The current state of hormonal therapy for prostate cancer.
        CA Cancer) Clin. 2002; 52: 154-179
        • Vogelzang NJ
        • Chodak GW
        • Soloway MS
        • et al.
        • Zoladex Prostate Study Group
        Goserelin versus orchiectomy in the treatment of advanced prostate cancer: Final results of a randomized trial.
        Urology. 1995; 46: 220-226
        • d'Ancona FC
        • Debruyne FM
        Endocrine approaches in the therapy of prostate carcinoma.
        Hum Reprod Update. 2005; 11: 309-317
        • Plosker GL
        • Brogden RN
        Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormonerelated disorders.
        Drugs. 1994; 48: 930-967
        • Chrisp P
        • Sorkin EM
        Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders.
        DrugsAging. 1991; 1: 487-509
        • Sennello LT
        • Finley RA
        • Chu SY
        • et al.
        Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration.
        J Pharm Sci. 1986; 75: 158-160
        • Vance MA
        • Smith Jr, JA
        Endocrine and clinical effects of leuprolide in prostatic cancer.
        Clin Pharmacol Ther. 1984; 36: 350-354
        • Sartor O
        Eligard: Leuprolide acetate in a novel sustained-release delivery system.
        Urology. 2003; 61: 25-31
        • Jocham D
        Leuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: Long-term follow-up results.
        Urol Int. 1998; 60 (discussion 35): 18-24
        • Sharifi R
        • Bruskewitz RC
        • Gittleman MC
        • et al.
        Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer.
        Clin Ther. 1996; 18: 647-657
        • Sharifi R
        • Browneller R
        • Leuprolide Study Group
        Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer.
        J Urol. 2002; 168: 1001-1004
        • Sharifi R
        • Soloway M
        • Leuprolide Study Group
        Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer.
        J Urol. 1990; 143: 68-71
        • Sharifi N
        • Gulley JL
        • Dahut WL
        Androgen deprivation therapy for prostate cancer.
        JAMA. 2005; 294: 238-244
        • Perez-Marreno R
        • Chu FM
        • Gleason D
        • et al.
        A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer.
        Clin Ther. 2002; 24: 1902-1914
        • Kienle E
        • Lubben G
        • German Leuprorelin Study Group
        Efficacy and safety of leuprorelin acetate depot for prostate cancer.
        Urol Int. 1996; 56: 23-30
        • Chu FM
        • Jayson M
        • Dineen MK
        • et al.
        A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer.
        J Urol. 2002; 168: 1199-1203
      2. Micro capsules forsustained release of drugs, European Patent Specification. European Patent Office. Patent N. EP1151746B1. Accessed February 4, 2010
        • Leitner JM
        • Mayr FB
        • Spiel AO
        • et al.
        The pharmacokinetics and pharmacodynamics of a new sustained-release leuprolide acetate depot compared to market references.
        Int J Gin Pharmacol Ther. 2008; 46: 407-414
        • Oken MM
        • Creech RILL Tormey DC
        • et al.
        Toxicity and response criteria of the Eastern Cooperative Oncology Group.
        Am J Clin Oncol. 1982; 5: 649-655
      3. Mixject, Medimop Medical Projects Ltd., West Pharmaceutical Services, USA. Accessed February 2, 2010
      4. European Medicines Agency (EMEA), Committee for Medicinal Products for Human Use (CHMP). Guideline on validation of bioanalytical methods. Draft (CHMP/EWP/192217/2009). Accessed March 11, 2010
      5. US Dept of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CIDER), Center for Veterinary Medicine (CVM). Guidance for Industry: Bioanalytical Method Validation. May 2001. Accessed March 11, 2010
      6. European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the investigation of bioavailability and bioequivalence. London, 26 July 2001. Accessed March 22, 2010
      7. MedDRA MSSO. Medical Dictionary for Regulatory Activities Maintenance and Support Services Organization. Accessed March 17, 2010
      8. American Cancer Society/National Comprehensive Cancer Network. Prostate cancer. Treatment guidelines for patients. Version VI/October 2007. Accessed March 18, 2010
        • Heyns CF
        • Simonin MP
        • Grosgurin P
        • et al.
        Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer.
        BJU Int. 2003; 92: 226-231
        • Thompson IM
        Flare associated with LHRH-agonist therapy.
        Rev Urol. 2001; 3: S10-S14
        • Bubley GJ
        Is the flare phenomenon clinically significant?.
        Urology. 2001; 58: 5-9
        • Calais da Silva FE
        • Bono AV
        • Whelan P
        • et al.
        Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: Results from a randomized phase 3 study of the South European Uroncological Group.
        Eur Urol. 2009; 55: 1269-1277
      9. European Medicines Agency (EMEA). International Conference on Harmonisation (ICH) Topic E10: Note for Guidance on Choice of Control Group in Clinical Trials (CPMP/ICH/364/96). January 2001.. Accessed March 11, 2010